Biotech
Monday, October 23rd, 2023 2:30 pm EDT
Key Points
- Roche’s Acquisition of Telavant: Swiss healthcare company Roche has announced its intention to acquire Telavant Holdings in a substantial $7.1 billion transaction.
- Telavant’s Expertise: Telavant specializes in producing drugs for individuals suffering from inflammatory and fibrotic diseases, including their development of a promising therapy for Crohn’s disease.
- Development of Inflammatory Bowel Disease Therapy: Roche, upon gaining full rights to Telavant’s RVT-3101 drug, aims to initiate global Phase 3 trials for the treatment of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease, based on promising data. Additionally, Roche will collaborate with Pfizer on a new drug for inflammatory bowel disease.
Swiss healthcare company Roche is set to acquire Telavant Holdings in a $7.1 billion deal. Telavant specializes in producing drugs for individuals with inflammatory and fibrotic diseases, with a focus on developing a promising therapy for Crohn’s disease. Roche will gain full rights to the RVT-3101 drug, a treatment under development for inflammatory bowel disease. The company plans to initiate global Phase 3 trials, involving clinical testing on a significant number of patients with conditions like ulcerative colitis and Crohn’s disease. Additionally, Roche will have the option to collaborate with Pfizer on a new drug for inflammatory bowel disease.
For the full original article on CNBC, please click here: https://www.cnbc.com/2023/10/23/roche-agrees-7point1-billion-deal-to-buy-telavant-holdings.html
